Medical Equipment
POMDOCTOR LIMITED Accelerates AI-Enabled Chronic Disease Management and RWD Commercialization
GUANGZHOU, China, Sept. 30, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an update on the continued progress in the development and commercialization of its AI...
2026-09-30 20:00
1116
2026 International Day of Older Persons: Dimora Medical Supports Dignified Longevity with Advanced Home Wound Care
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- As the world observes the 2026 United
Nations International Day of Older Persons under the theme "The Age of
Longevity: Rethinking Systems for Longer Lives
2026-09-30 01:50
1959
Yuyu Teijin Medicare Uses Drones to Deliver Medical Supplies to Patients on Korea's Remote Islands
SEOUL, South Korea, Sept. 29, 2026 /PRNewswire/ -- Yuyu Teijin Medicare, a home healthcare joint venture between Yuyu Pharma of Korea and Teijin Pharma of Japan, has completed a pilot delivery of medical supplies by drone to a ventilator patient living on a remote Korean island. In the test, a d...
2026-09-29 21:00
1631
Elsevier launches ClinicalKey Nursing AI, a new evidenced-based clinical AI solution built specifically for nurses
Developed to fit around nursing workflows, ClinicalKey Nursing AI gives nurses fast, traceable answers to clinical questions at the point of care. NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Today Elsevier announced the global launch of ClinicalKey Nursing AI, the clinical AI tool built specifically...
2026-09-29 20:00
1520
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
* HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing * Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharm...
2026-09-29 13:12
1712
Open-Source Model Accelerates Global Progress in Medical Video AI
SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- Through an open-source model, a public dataset and benchmark, and the MedVidU Challenge, a global research competition, researchers worldwide now share a common foundation for advancing medical video AI. The Challenge drew 75 teams from 18 countries and re...
2026-09-28 21:19
3031
Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region
Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale SEOUL, South Korea, Sept. 28, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnost...
2026-09-28 21:00
1829
SOLA Biosciences Japan Receives AMED Grant to Advance SOL-257, Innovative Gene Therapy Aiming to Restore TDP-43 Function for ALS Patients
TOKYO and BOSTON, Sept. 28, 2026 /PRNewswire/ -- SOLA Biosciences Japan GK ("SOLA Japan"), the wholly owned Japanese subsidiary of Boston-based SOLA Biosciences Inc. (together, "SOLA"), announced that it has been awarded a grant of approximately 6 billion yen over five years by the Japan Agency f...
2026-09-28 14:00
1969
GROWNSY Makes NANN Conference Debut, Partners with NANN and Pediatrician Dr. Molly O'Shea on NANNcast Episode Tackling Infant Nasal Congestion
The company exhibited for the first time at NANN's 42nd Annual Conference in West Palm Beach and will sponsor a NANNcast episode exploring why newborns are so vulnerable to nasal congestion — and what neonatal nurses and parents can do about it. NEW YORK, Sept. 22, 2026 /PRNewswire/ -- GROWNSY <...
2026-09-23 09:36
817
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive global ...
2026-09-22 12:00
1940
NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
* ImpriMed combines ex vivo functional testing with multimodal AI to support personalized cancer treatment decisions and drug development * The investment is part of ImpriMed's $10 million Series A2 bridge round as the company advances U.S. commercialization and expands into Asia * NAVER D2S...
2026-09-18 23:00
3337
Dr. Alison Armour agrees to become Chief Medical Officer of Alpha Fusion, as Company Advances Integration of At-211 Businesses with Curadh MTR
— Combining Both Companies' Astatine At-211 Assets, Development Capabilities, and Supply Chains to Create a Global Targeted Alpha Therapy Company — TOKYO, Sept. 17, 2026 /PRNewswire/ -- Alpha Fusion Inc. ("Alpha Fusion"), a clinical-stage company with an advanced At-211 drug platform, and Curadh ...
2026-09-17 19:00
2319
PAINSTUDY Inc. Expands Functional Patch Lineup for Everyday Muscle and Joint Care
Functional healthcare brand builds on domestic online market experience to broaden product lineup, distribution channels, and eye global wellness market entry SEOUL, South Korea, Sept. 15, 2026 /PRNewswire/ -- Functional healthcare brand PAINSTUDY Inc. is strengthening its product competitivenes...
2026-09-16 08:00
1610
Yuyu Pharma Expands Solar Power at Manufacturing Facility, Bringing On-Site Capacity to 1 MW
New solar installation expected to supply more than 30% of the factory's electricity needs and pay for itself in approximately three years SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) has completed a major expansion of solar power at its manufacturing facility in ...
2026-09-14 21:00
3250
NEXTBIOMEDICAL Marks Its Largest-Ever Presence at CIRSE 2026 with Exhibition Booth and Learning Center, Highlighting Global Clinical Evidence
SEOUL, South Korea, Sept. 14, 2026 /PRNewswire/ -- NEXTBIOMEDICAL, a medical device company specializing in innovative therapeutic solutions, participated in CIRSE 2026, the annual congress of the Cardiovascular and Interventional Radiological Society of Europe, held in Copenhagen, Denmark, from ...
2026-09-14 21:00
4076
Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
* Enabled by Altruist's integrated CMC development platform, GMP manufacturing and regulatory service capabilities, LP-003 has successfully advanced from concept to potential commercialization. * LP-003 is the first innovative drug independently developed by LongBio Pharma to advance to BLA s...
2026-09-14 21:00
3122
POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today a...
2026-09-10 20:00
2511
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...
2026-09-09 20:25
2469
Flysound Brings B02 Open-Fit AI Hearing Aid to the U.S.
* An open-fit AI hearing aid designed for those unable or unwilling to wear in-ear devices SHERIDAN, Wyo., Sept. 7, 2026 /PRNewswire/ -- Hearing loss affects hundreds of millions of people worldwide, yet many existing hearing solutions remain designed around a single assumption: that users can ...
2026-09-08 13:57
1459
Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...
2026-09-07 17:42
2538
Week's Top Stories
Most Reposted
Agoda Releases AI Developer Report 2026: Agentic AI Adoption Outpaces Enterprise Readiness Across Southeast Asia and India
[Picked up by 294 media titles]
2026-09-24 10:30
Malaysia Calls for Shift from Halal-Certified to Halal-Competitive as ASEAN Targets USD5 Trillion Global Halal Economy
[Picked up by 277 media titles]
2026-09-25 14:45
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 276 media titles]
2026-09-29 09:00
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 276 media titles]
2026-09-28 23:04
DOKU Names Himelda Renuat CEO as Ant International's Antom Deepens Strategic Investment in Indonesia's Payments Leader
[Picked up by 274 media titles]
2026-09-24 10:00
Most Read
Brightray Signs Prefabricated Module Sales Framework Agreement for Planned 40MW AI Data Center Project in Macao
2026-09-25 20:30
13806
Envision Energy Secures TÜV SÜD Certificate for Wind Farm Control System, Strengthening Long-Term Resilience for Future Energy Systems
2026-09-25 20:11
12522
ULTRALOQ Launches Next-Generation Smart Lock Collection: Refining Home Entry with Natural, Intelligent and Trusted Access Solutions
2026-09-26 02:46
11554
